Lupin

Lupin announced the launch of Dasatinib tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, in the United States, following…

Lupin announced a strategic collaboration with TB Alliance, a nonprofit drug developer, to advance the clinical development and…

Lupin announced that it has received the highest ‘A’ leadership rating from Climate Disclosure Project (CDP) for its exceptional…

Lupin announced a licensing and supply agreement through its subsidiary Lupin Atlantis Holdings SA (LAHSA) with Galenicum Health,…

Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has…

The product will be manufactured at Lupin’s biotech facility in Pune, which was inspected by the U.S. FDA prior to approval

Lupin announced that the United States Food and Drug Administration (US FDA) has completed a product specific Pre-Approval…

The Establishment Inspection Report follows a product-specific Pre-Approval Inspection conducted by the U.S. FDA at Lupin’s…

Lupin announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration…

Lupin to share findings on LNP3693’s safety, pharmacokinetics, and anti-tumour activity in advanced solid tumours and lymphoma at…